Beam Therapeutics
BEAM
185 hedge funds and large institutions have $1.88B invested in Beam Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 64 increasing their positions, 56 reducing their positions, and 38 closing their positions.
74% more call options, than puts
Call options by funds: $9.99M | Put options by funds: $5.74M
16% more capital invested
Capital invested by funds: $1.62B → $1.88B (+$254M)
14% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 56
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.56% less ownership
Funds ownership: 85.14% → 84.57% (-0.56%)
5% less funds holding
Funds holding: 194 → 185 (-9)
16% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$91M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$17.8M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$17.8M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$15.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$30.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$29M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$24.4M |
| 4 |
HH
HSG Holding
Na,
Hong Kong
|
-$19.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$10.8M |
BEAM Hedge Fund Activity: Q4 2023 in Review
185 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q4 2023, worth a combined $1.88B — up 16% from $1.62B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of BEAM and 32 opened new positions — a net loss of 6 holders — while 56 trimmed existing stakes and 64 added.
The largest buyer was Morgan Stanley, adding an estimated $91M. The largest seller was Temasek Holdings, cutting an estimated $30.8M.
- 185 institutional investors held Beam Therapeutics (BEAM) as of Q4 2023, down from 194 in Q3 2023.
- Funds reported $1.88B of Beam Therapeutics stock for Q4 2023, up 16% quarter-over-quarter.
- 32 funds opened new Beam Therapeutics positions in Q4 2023 and 38 closed out, a net change of -6 holders.
- The largest Beam Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $91M added.
- The largest Beam Therapeutics seller in Q4 2023 was Temasek Holdings, an estimated $30.8M sold.
Based on aggregated 13F filings for Q4 2023.